Community Bank & Trust Waco Texas Has $323,000 Position in Bristol-Myers Squibb Company (BMY)
Community Bank & Trust Waco Texas continued to hold its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,800 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Community Bank & Trust Waco Texas’ holdings in Bristol-Myers Squibb were worth $323,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp increased its stake in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after buying an additional 1,223,457 shares during the period. Jennison Associates LLC increased its stake in shares of Bristol-Myers Squibb by 5.4% in the 2nd quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock valued at $1,288,179,000 after buying an additional 1,184,652 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Bristol-Myers Squibb by 18.7% in the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after buying an additional 2,451,390 shares during the period. Legal & General Group Plc grew its stake in shares of Bristol-Myers Squibb by 2.7% during the second quarter. Legal & General Group Plc now owns 8,431,348 shares of the biopharmaceutical company’s stock worth $469,802,000 after purchasing an additional 217,920 shares during the period. Finally, Swiss National Bank grew its stake in shares of Bristol-Myers Squibb by 3.2% during the second quarter. Swiss National Bank now owns 6,111,570 shares of the biopharmaceutical company’s stock worth $340,537,000 after purchasing an additional 189,900 shares during the period. 68.97% of the stock is owned by institutional investors.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.23% of the stock is currently owned by corporate insiders.
A number of equities research analysts recently commented on the company. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. SunTrust Banks, Inc. raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Credit Suisse Group reissued a “hold” rating and issued a $61.00 target price (up from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Thursday, October 26th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $64.93.
Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $60.80 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $66.10. The firm has a market capitalization of $99,510.00, a price-to-earnings ratio of 20.72, a price-to-earnings-growth ratio of 2.42 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 22.99% and a net margin of 16.29%. The business had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter in the previous year, the company earned $0.77 earnings per share. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. equities analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date of this dividend was Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is 61.42%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.